Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
[powerpress]